<![CDATA[Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy]]>
Aromatase inhibitors may be an optimal choice for adjuvant endocrine therapy (ET) among patients with with hormone receptor-positive (HR+), HER2-positive (HER2+) early breast cancer over selective estrogen receptor modulators (SERMs), according to …